Over the past decade, oncology has seen unprecedented innovation: treatment paradigms are shifting from tumour- to mutation- and biomarker-based paradigms, and gene editing is now within the realm of the possible. Today, healthcare stakeholders have already started recognising the transformation of single biomarker testing to next-generation sequencing (NGS) testing, to simplify the personalised treatment plan at beginning of diagnosis.